Uvax Bio Announces Interim Results from a Phase 1 Clinical Trial Evaluating its HIV-1 Vaccine November 19, 2024 by | NEWARK, Del.–(BUSINESS WIRE)–Uvax Bio, LLC Phase 1 HIV-1 Vaccine Interim Analysis #1
